INDICLOR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDICLOR is an injectable diagnostic or therapeutic agent developed by GE HealthCare and approved in 1992. The specific mechanism of action and clinical indications are not publicly detailed in available data. This product operates in a mature market segment with established clinical utility.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30/100) suggests team focus shifting toward line extensions, cost management, or transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest limited near-term hiring for this product, typical of LOE-stage assets. Career opportunities will focus on efficiency, market defense, and transition planning rather than growth initiatives.
Brand ManagerProduct Manager
Worked on INDICLOR at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.